Amphetamine Stimulant denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for amphetamine stimulant are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Requires Prior Authorization for Amphetamine Stimulants — and How to Navigate It

Prior authorization (PA) for amphetamine stimulants is one of the most common administrative barriers in ADHD treatment. UnitedHealthcare requires PA for this drug class to verify that the prescription meets clinical coverage criteria before the claim is paid. A denial issued for "prior authorization required" typically means either that no PA was submitted before dispensing, that a submitted PA was denied on clinical grounds, or that a prior PA expired and was not renewed. Unlike some denial types, a prior-auth-required denial is often correctable — but timing matters, because you are usually responsible for costs incurred while the PA process is pending.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503): If a PA request was denied (rather than simply not submitted), you have the right to a full-and-fair internal review. The plan must provide the specific clinical criteria that were not met and give you an opportunity to submit additional evidence.
• External review (ACA §2719): If the internal appeal is denied, you may request independent external review within the window stated in your denial letter (typically approximately 180 days from the final internal denial).
• Expedited review: If the patient's condition is urgent — for example, if untreated ADHD poses a safety risk — request expedited review. Plans must typically respond within 72 hours.
• Concurrent/retroactive review: If the medication was dispensed before PA was obtained, ask UHC whether a retroactive PA review is available. Outcomes vary, but it is worth requesting before appealing.

## Documentation to Gather

1. Diagnosis confirmation — A comprehensive evaluation confirming the diagnosis for which the stimulant was prescribed, including the evaluating clinician's credentials and the date of evaluation. 2. Prescriber PA support letter — A letter from the treating physician documenting the clinical basis for the prescription, the patient's diagnosis and severity, and how the request meets the FDA-approved indication. 3. Prior treatment history — Records of all prior medications tried, with dates and outcomes, to satisfy any step-therapy requirements embedded in UHC's PA criteria. 4. Functional-impairment documentation — Chart notes describing the impact of untreated symptoms on daily life, supporting urgency if an expedited review is requested. 5. UHC PA criteria checklist — Request UHC's prior-authorization clinical criteria for amphetamine stimulants and ensure every criterion is addressed in the submission.

## Criteria-Mapping Strategy

Obtain UHC's PA clinical criteria before submitting (available from UHC's provider portal or by calling the PA line). List each criterion. Prepare a chart-based response for each one. A PA submission that proactively addresses every criterion — rather than submitting a bare prescription — is far less likely to be denied. If a prior PA was denied, use the criteria-map format for your appeal to show exactly where the prior submission fell short and how the new evidence fills that gap.